RxDoctor Payments Data

David Coll, MD

Vascular Surgery · Baltimore, MDNPI 1104835479

Payments from drug & device makers

$1,351in general payments, 2019–2025

Across 47 payments — averaging $28.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$353
  • Johnson & Johnson$206
  • Smith+Nephew$157
  • Boston Scientific$154
  • W. L. Gore & Associates, Inc.$135
  • Keswick Pharmaceuticals LLC$114
  • plus $232 from 8 others

What the payments were for

  • Food & beverage$1,351100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,351 in reported general payments places this provider in the 30th percentile of 104 vascular surgery providers in Maryland.

See all vascular surgery providers in Maryland

Medicare billing

Part B allowed, 2024
$804,899
Medicare patients
1,581
Services billed
3,689

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban71$68,280
EliquisApixaban32$34,082
Cilostazol153$4,314
ClopidogrelClopidogrel Bisulfate153$2,425
Oxycodone Hcl28$483
Atorvastatin Calcium27$347
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen40$344
Gabapentin15$282
Tramadol Hcl54$254
Cephalexin14$218

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$206$68,28071 claims
PfizerEliquis$17$34,08232 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 104 vascular surgery providers in Maryland.

Other vascular surgery in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →